SCANDIUS BIOMEDICAL ANNOUNCES NEW TRITIS TIBIAL FIXATION SYSTEM FOR SOFT TISSUE ACL RECONSTRUCTION

Scandius BioMedical, Inc. announced today that its TriTis Tibial Fixation System has been granted 510(k) market clearance by the U.S. Food and Drug Administration (FDA) and has been used successfully in Anterior Cruciate Ligament (ACL) reconstruction, the single largest sports-related orthopedic joint injury.
PR Newswire